Coherus BioSciences

We have a unique combination of intellectual assets, commercial capabilities, global reach and strategic focus required to successfully develop and market biosimilar drugs. Founded in 2010 as a pure-play biosimilar platform company, Coherus is devoted to expanding patient access to these life-changing therapeutics in major regulated markets around the world. Indeed, we believe Coherus is the only standalone biosimilars company with the insights and assets needed to succeed in this mission. Our platform includes world-class capabilities in process science, analytical characterization, protein production, and clinical and regulatory development. What’s more, our scientific and commercial goals are grounded in the expertise of an elite team of industry veterans, supported from the outside by top-tier global biopharmaceutical partners.
Company Growth (employees)
Type
Public
HQ
Redwood City, US
Founded
2010
Size (employees)
132 (est)-21%
Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US

Key People/Management at Coherus BioSciences

S. Edward Torres

S. Edward Torres

Investor
Dennis M. Lanfear

Dennis M. Lanfear

Chairman
Ann M. Lowe

Ann M. Lowe

Senior Vice President of Oncology

Coherus BioSciences Office Locations

Coherus BioSciences has an office in Redwood City
Redwood City, US (HQ)
600 333 Twin Dolphin Dr
Show all (1)

Coherus BioSciences Financials and Metrics

Coherus BioSciences Financials

Coherus BioSciences's revenue was reported to be $190.1 m in FY, 2016
USD

Net income (Q2, 2017)

(55.4 m)

EBIT (Q2, 2017)

(56.6 m)

Market capitalization (22-Dec-2017)

516.4 m

Cash (30-Jun-2017)

73.4 m
Coherus BioSciences's current market capitalization is $516.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

31.1 m30 m190.1 m

Revenue growth, %

(3%)533%

R&D expense

78.2 m213.1 m254.4 m

General and administrative expense

17.6 m36 m51.6 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

12.4 m14.1 m

R&D expense

18.5 m36.5 m56.9 m68.2 m65.3 m65.5 m64.6 m53.8 m34.5 m

General and administrative expense

4 m6.1 m8.8 m10.2 m11.4 m11.3 m13.6 m18.8 m23.5 m

Operating expense total

22.5 m42.6 m65.8 m78.4 m76.7 m76.8 m78.2 m72.6 m58 m
USDFY, 2014FY, 2015FY, 2016

Cash

150.4 m158.2 m124.9 m

Inventories

1.9 m

Current Assets

179.1 m197.4 m161.5 m

PP&E

4.5 m10.5 m10.8 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

100.9 m115.1 m206.1 m153.7 m179.6 m220.9 m159.7 m124.9 m73.4 m

Current Assets

118.9 m143.9 m239.6 m189.3 m211.6 m236.8 m177.3 m208.3 m153.3 m

PP&E

3.7 m5.1 m6.3 m8.7 m10.3 m9.9 m10.7 m14.9 m14.5 m

Goodwill

943 k943 k943 k943 k943 k943 k943 k943 k943 k
USDFY, 2014FY, 2015FY, 2016

Net Income

(87.2 m)(223.9 m)(127.8 m)

Depreciation and Amortization

674 k3 m

Accounts Payable

3.6 m(5 m)

Cash From Operating Activities

(23.9 m)(252.5 m)
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(7.9 m)(40.8 m)(99.9 m)(171.4 m)(65.5 m)(135.7 m)(51.8 m)(74.8 m)(130.2 m)

Depreciation and Amortization

632 k1.3 m717 k1.4 m2.2 m865 k1.7 m

Accounts Payable

4.4 m10.9 m7.1 m19.1 m(6.8 m)(7.4 m)(1.6 m)(7.3 m)(3.8 m)

Cash From Operating Activities

(53.9 m)(113.6 m)(76.3 m)(103.7 m)(165.7 m)(73.3 m)(128.9 m)
Y, 2017

Financial Leverage

5.6 x
Show all financial metrics

Coherus BioSciences Market Value History

Coherus BioSciences's Web-traffic and Trends

You may also be interested in